Drug

Description

Enasidenib

Drug for the treatment of adult patients with recurrent or refractory acute myeloid leukemia with a mutation in isocitrate dehydrogenase 2 (IDH2). Acts as an allosteric inhibitor of the mutant form of IDH2.

Dimorpholamine

CNS stimulator. Ingredient of Theraptique (Japan). Stimulates the respiratory and circulatory centers and increases respiratory volume and blood pressure.

Edatrexate

Drug with antineoplastic activity. Dihydrofolate reductase inhibitor.

Inositol nicotinate

Vasodilator drug. Reduces or prevents a flush of blood, slowly breaking down into metabolites of niacin (nicotinic acid) and inositol. In Europe, Hexopal is used for the symptomatic treatment of severe intermittent claudication and Raynaud's phenomenon.

Stallimycin

Oligopeptide antineoplastic antibiotic isolated from the bacterium Streptomyces distallicus. Preferentially binds to AT rich sequences in the minor groove of DNA

Brigatinib

Brigatinib is an orally available inhibitor of receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) tyrosine kinase with potential antineoplastic activity.

Neratinib

Dual inhibitor of receptor tyrosine kinases: the human epidermal growth factor receptor 2 (Her2) and epidermal growth factor receptor (EGFR) kinases with potential antineoplastic activity.

Dalargin

Anti-ulcer drug with antisecretory activity

Indinavir

Inhibitor of HIV protease

Telaprevir

Inhibitor of hepatitis C protease